Skip to main contentSkip to navigation
Print subscriptions
Newsletters
Sign in

AstraZeneca

September 2026

  • The City of London skyline.

    Business live
    UK government pays highest interest rate on 10-year debt since 1999 at bond auction – as it happened

  • Tablets on a pharmaceutical production line

    European drugmakers say they are ‘losing ground’ to US and Chinese rivals

August 2026

  • Nils Pratley

    Nils Pratley on finance
    Soriot should explain the curious case of AstraZeneca’s non-deal

    Nils Pratley
    AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders
  • Nils Pratley

    Nils Pratley on finance
    AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

    Nils Pratley
    The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling
  • Gloved hands hold a clear laboratory plate filled with rows of small sample tubes

    AstraZeneca falls to third-largest UK company amid US merger talks

    Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

July 2026

  • Pascal Soriot

    AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’

    Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot

June 2026

  • A woman touching her abdomen in pain

    Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

  • The artist Tracey Emin.

    Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery

April 2026

  • Test tubes and pipette displayed in front of AstraZeneca logo

    AstraZeneca makes surprise U-turn with £300m pharma investment in UK

    Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

March 2026

  • Imperial Chemical Industries (ICI) chief executive Ronnie Hampel adjusts his tie before a press conf.., 1994-07-28 (photo)REU7668211 Imperial Chemical Industries (ICI) chief executive Ronnie Hampel adjusts his tie before a press conf.., 1994-07-28 (photo); (add.info.: Imperial Chemical Industries (ICI) chief executive Ronnie Hampel adjusts his tie before a press conference to announce the company\'s interim results July 28); REUTERS/Kevin Lamarque.

    Sir Ronnie Hampel obituary

  • MRSA bacteria strain in a petri dish in a microbiological laboratory

    Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

February 2026

  • Pascal Soriot, Chief Executive of Astra Zeneca

    AstraZeneca boss Pascal Soriot’s pay rises to £17.7m

  • Pascal Soriot, chief executive of AstraZeneca

    AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

January 2026

  • The company said it would spend the money by 2030 to expand medicines manufacturing and research and development in China.

    AstraZeneca to invest £11bn in China after rowing back on UK expansion

    Keir Starmer says the move, announced during his trip to Beijing, will help support thousands of British jobs

December 2025

  • Emma Walmsley

    US is the best place for drug companies to invest, says boss of London-based GSK

    Emma Walmsley’s praise for US pharmaceutical market piles pressure on UK government

November 2025

  • A female pharmacist at work in a chemist

    NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

  • Nils Pratley

    Nils Pratley on finance
    Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares

    Nils Pratley

September 2025

  • Nils Pratley

    Nils Pratley on finance
    AstraZeneca’s listing rejig spells long-term danger for London

    Nils Pratley
    It’s not skipping off entirely to New York, but pharma giant sets a worrying precedent for UK stock market
  • a pipette drips fluid into a line of test tubes with the AstraZeneca’s logo in the background

    AstraZeneca to upgrade US listing in ‘knock-back for London’

    UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge
  • Prescription bottle filled with green capsules

    UK set on resolving standoff with big pharma, science minister says

    Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment
About 1,111 results for AstraZeneca
1234...
Explore more on these topics